.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Julphar
Queensland Health
Johnson and Johnson
UBS
Harvard Business School
Federal Trade Commission
McKinsey
Chubb
Chinese Patent Office

Generated: November 17, 2017

DrugPatentWatch Database Preview

REQUIP Drug Profile

« Back to Dashboard

Which patents cover Requip, and when can generic versions of Requip launch?

Requip is a drug marketed by Glaxosmithkline Llc and is included in two NDAs. There are two patents protecting this drug and nine Paragraph IV challenges.

The generic ingredient in REQUIP is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-001Sep 19, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-006Apr 10, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-005Oct 31, 2008ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-005Sep 19, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
REQUIP
ropinirole hydrochloride
TABLET;ORAL020658-004Sep 19, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-002Jun 13, 2008DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-004Jun 13, 2008ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-001Jun 13, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-006Apr 10, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
REQUIP XL
ropinirole hydrochloride
TABLET, EXTENDED RELEASE;ORAL022008-003Jun 13, 2008ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for REQUIP

Drugname Dosage Strength RLD Submissiondate
ropinirole hydrochloride*Extended-release Tablets3 mgRequip XL1/8/2009
ropinirole hydrochlorideExtended-release Tablets6 mgRequip XL7/22/2009
ropinirole hydrochlorideExtended-release Tablets12 mgRequip XL2/5/2009
ropinirole hydrochlorideExtended-release Tablets3 mgRequip XL1/8/2009
ropinirole hydrochlorideExtended-release Tablets8 mgRequip XL11/3/2008
ropinirole hydrochlorideExtended-release Tablets4 mgRequip XL10/31/2008
ropinirole hydrochloride Extended-release Tablets2 mgRequip XL10/14/2008
ropinirole hydrochlorideTablets3 mg, 4 mg and 5 mgRequip2/4/2005
ropinirole hydrochlorideTablets0.25 mg, 0.5 mg, 1 mg and 2 mgRequip12/22/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
QuintilesIMS
Dow
US Department of Justice
Chubb
Cerilliant
Colorcon
Chinese Patent Office
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot